Skip to main content
    S

    Scinai Immunotherapeutics Ltd (SCNI)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.37
    -0.03 (-8.19%)

    Market Cap: $1.05M

    Last updated: Nov 17, 2026 at 4:29 PM ET

    Scinai Immunotherapeutics Ltd (SCNI) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Scinai Immunotherapeutics (SCNI) has a market cap of $1.05M. Revenue grew 112.34% over the last 12 months from the 12 months before. It holds $1.05M more cash than debt, 100.27% of its market cap.

    Total Valuation

    Market Cap$1.05M
    Latest price (Nov 17, 2026)$0.37

    Key Dates

    Last Earnings DateJul 7, 2026
    Fiscal Year EndDecember

    Price Statistics

    The stock is down 96.21% over 52 weeks and trades 64.08% below its 50-day average.

    Beta (1Y)1.58
    52-Week Change-96.21%
    1-Month Change-50.53%
    3-Month Change-86.46%
    6-Month Change-92.70%
    5-Year Change-99.98%
    10-Year Change-99.99%
    Total Return (1Y)-96.21%
    Total Return (3Y CAGR)-81.93%
    Total Return (5Y CAGR)-82.28%
    Max Drawdown (1Y)-97.01%
    Max Drawdown (3Y)-99.51%
    Sharpe Ratio (1Y)-2.48
    Correlation with SPY (1Y)0.16
    50-Day Average$1.03
    200-Day Average$3.91
    52-Week Range$0.39 to $13.00
    RSI (14 Days)24.3
    Average Volume (20 Days)89.86K

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 1.23x current liabilities, and total debt is 0.06x shareholder equity.

    Current Ratio1.23x
    Quick Ratio1.23x
    Debt / Equity0.06x
    Interest Coverage-22.81x

    Returns and Efficiency

    Return on invested capital is -61.86% over the last 12 months, against a 5-year average of -39.53%.

    Return on Equity (ROE)-23.33%
    Return on Assets (ROA)-15.93%
    Return on Invested Capital (ROIC)-61.86%
    ROA (5Y Average)-26.61%
    ROIC (5Y Average)-39.53%
    Asset Turnover0.22x
    Receivables Turnover22.11x

    Scores

    SCNI has an Altman Z-Score of -12.89, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.

    Altman Z-Score-12.89
    Altman Z ZoneDistress
    Piotroski F-Score2 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $3.07M over the last 12 months.

    Revenue$3.07M
    Revenue Growth (YoY)+112.34%
    Gross Profit-$3.73M
    Operating Income-$8.50M
    Pretax Income-$2.50M
    Net Income-$2.50M

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 68.22% of the $15.70M in total assets.

    Cash and Equivalents$1.71M
    Total Debt$657.00K
    Net Cash$1.05M
    Working Capital$443.00K
    Shareholder Equity$10.71M
    Total Assets$15.70M
    Total Liabilities$4.98M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $240.81K of capital spending, operating cash flow left -$7.33M of free cash flow.

    Operating Cash Flow-$7.09M
    Capital Expenditures$240.81K
    Free Cash Flow-$7.33M
    FCF Per Share-$2.79
    Depreciation and Amortization$1.93M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -276.49%.

    Gross Margin-121.44%
    Operating Margin-276.49%
    Pretax Margin-81.34%
    Net Margin-81.34%
    FCF Margin-238.58%

    Dividends and Yields

    SCNI does not pay a dividend. Its free cash flow yield is -8217.58%.

    FCF Yield-8217.58%
    Shareholder Yield0.00%

    Stock Splits

    The last split was a 1-for-10 reverse split on Aug 21, 2026.

    Last Split DateAug 21, 2026
    Split TypeReverse split
    Split Ratio1:10

    Peer Position

    Against 6 similar companies, SCNI has the 4th highest ROIC.

    ROIC-61.86% vs -91.59% median
    Revenue Growth (Trailing 4 Quarters, YoY)+112.34% vs -100.00% median

    Competitors compared

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About SCNI

    What is SCNI's market cap?

    Scinai Immunotherapeutics has a market cap of $1.05M.

    How many shares of SCNI are outstanding?

    Scinai Immunotherapeutics has 240.53K shares outstanding.

    Does SCNI pay a dividend?

    No. Scinai Immunotherapeutics does not pay a dividend.

    How much debt does SCNI have?

    Scinai Immunotherapeutics has $657.00K of total debt and $1.71M of cash and equivalents, a net cash position of $1.05M.